secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0000950170-23-023380
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports Q1 net income of $6.2M; cash $17.7M; IND work ongoing
--------------------------------------------------------------------------------

- Q1 2023 net income $6.2M ($2.79 basic EPS) vs net loss $6.6M in Q1 2022; driven by $7.7M warrant liability gain.
- Cash and equivalents $17.7M at March 31, 2023, up from $5.3M at Dec 31, 2022; net cash used in ops $1.6M.
- Management expects existing cash to fund operations through June 2024.
- IND and clinical enabling studies for REVTx-300 and REVTx-100 underway; Phase 1 start targeted Q4 2023.
- Decreased clinical study expenses due to completion of prior Phase 2b and Phase 1b studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/0000950170-23-023380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/revb-20230522.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-023380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer